NOTIFICATION TO STOCK EXCHANGE
Company Statement
Bengaluru, Karnataka, India, Aug 31, 2019
“The U.S. FDA conducted a cGMP inspection at one of our Biologics Drug Product facilities in Bengaluru from Aug 22 to Aug 30, 2019. The inspection concluded with four observations which we believe will not impact supplies from this facility. We are confident of addressing these observations through a Corrective and Preventive Action plan in a timely manner.”
– Company Spokesperson
You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.
Download Company Statement